Physician profile
Zeena A Daniel
NPI 1083380414
$864.34
in general payments reported to CMS, 2019-2025
15 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.64 · 2022: $94.93 · 2023: $383 · 2024: $223 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $315.81 | 2023-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $81.49 | 2023-2025 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $75.05 | 2023-2025 | Austedo Xr, Austedo Xr |
| Exact Sciences Corporation | $71.36 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.89 | 2023-2024 | Caplyta |
| Abbvie INC. | $63.41 | 2022 | |
| Neurocrine Biosciences, INC. | $36.14 | 2023 | Ingrezza |
| Neurelis, INC. | $33.18 | 2024 | Valtoco |
| Bayer Healthcare Pharmaceuticals INC. | $23.82 | 2025 | |
| Pfizer INC. | $21.64 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.31 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.25 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $16.16 | 2024 | Trelegy Ellipta |
| Urovant Sciences INC | $15.21 | 2022 | |
| Axsome Therapeutics, INC. | $13.62 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeena Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.